Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012)
Susan H. Eshleman(Johns Hopkins University), J. Brooks Jackson(VA Tennessee Valley Healthcare System), Martin Mracna(United States Department of Health and Human Services), Francis Mmiro(Makerere University), Martina Deseyve(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Lynne Mofenson(Elizabeth Glaser Pediatric AIDS Foundation), Thomas R. Fleming(University of Washington), Mary Glenn Fowler(Johns Hopkins University), Shawn Cunningham(United States Department of Health and Human Services), Mark Mirochnick(Boston University), Laura Guay(Johns Hopkins University), Philippa Musoke(Centers for Disease Control and Prevention)
Cited by 422
Related Papers
Prevention of HIV-1 Infection with Early Antiretroviral Therapy
|New England Journal of Medicine|2011|7k
Antiretroviral Therapy for the Prevention of HIV-1 Transmission
|New England Journal of Medicine|2016|1.7k
Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial
|The Lancet|1999|1.7k
Targeted Anticytokine Therapy in Patients With Chronic Heart Failure
|Circulation|2004|1.2k